SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Krishnan, A. Articles by Forman, S. J. Search for Related Content PubMed PubMed Citation Articles by Krishnan, A. Articles by Forman, S. J. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 95 No. 5 (March 1), 2000: pp. 1588-1593 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors Amrita Krishnan, Smita Bhatia, Marilyn L. Slovak, Daniel A. Arber, Joyce C. Niland, Auayporn Nademanee, Henry Fung, Ravi Bhatia, Ashwin Kashyap, Arturo Molina, Margaret R. O'Donnell, Pablo A. Parker, Irena Sniecinski, David S. Snyder, Ricardo Spielberger, Anthony Stein, and Stephen J. Forman Divisions of Hematology and Bone Marrow Transplantation, Pediatric Oncology, Biostatistics and Pathology, City of Hope National Medical Center, Duarte, CA.     Abstract Top Abstract Introduction Results Discussion References We analyzed data on 612 patients who had undergone high-dose chemoradiotherapy (HDT) with autologous stem cell rescue for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the City of Hope National Medical Center, to evaluate the incidence of therapy-related myelodysplasia (t-MDS) or therapy-related acute myeloid leukemia (t-AML) and associated risk factors. A retrospective cohort and a nested case-control study design were used to evaluate the role of pretransplant therapeutic exposures and transplant conditioning regimens. Twenty-two patients developed morphologic evidence of t-MDS/t-AML. The estimated cumulative probability of developing morphologic t-MDS/t-AML was 8.6% ± 2.1% at 6 years. Multivariate analysis of the entire cohort revealed stem cell priming with VP-16 (RR = 7.7, P = 0.002) to be independently associated with an increased risk of t-MDS/t-AML. The influence of pretransplant therapy on subsequent t-MDS/t-AML risk was determined by a case-control study. Multivariate analysis revealed an association between pretransplant radiation and the risk of t-MDS/t-AML, but failed to reveal any association with pretransplant chemotherapy or conditioning regimens. However, patients who had been primed with VP-16 for stem cell mobilization were at a 12.3-fold increased risk of developing t-AML with 11q23/21q22 abnormalities (P = 0.006). Patients undergoing HDT with stem cell rescue are at an increased risk of t-MDS/t-AML, especially those receiving priming with VP-16 for peripheral stem cell collection. (Blood. 2000;95:1588-1593) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Results Discussion References High-dose chemoradiotherapy (HDT) with stem cell rescue has become the treatment of choice for patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) who have a suboptimal response to initial therapy or for patients with refractory or relapsed disease. Long-term disease-free survival rates of 40% to 50% are reported in patients treated with this approach.1-10 With improvement in survival following intensive therapy, posttransplant therapy-related myelodysplasia (t-MDS) and secondary therapy-related acute myeloid leukemia (t-AML) are emerging as serious long-term complications.11-18 The cumulative probability of t-MDS/ t-AML reported in the literature has ranged from 4% at 5 years15 to 18% at 6 years.16 Some of the risk factors predicting an increased risk of t-MDS/t-AML following transplant have included older age at transplant,14,17 radiation therapy,15,16 and a low platelet count at transplant.16 It is unclear whether t-MDS/t-AML is related to pretransplant chemotherapy and radiotherapy or is the result of transplant conditioning and stem cell priming regimens, or a cumulative effect of all of these exposures. This investigation analyzed data on 612 patients undergoing HDT with stem cell rescue for HD or NHL to evaluate whether pretransplant therapeutic exposures or transplant conditioning and stem cell priming regimens were associated with an increased risk of t-MDS/t-AML. Patients and methods Both a retrospective cohort and a nested case-control study design were used to evaluate the role of pretransplant therapeutic exposures, stem cell priming, and transplant conditioning regimens in the development of t-MDS/t-AML. Cohort analysis Between 1986 and 1998, 612 patients received HDT with autologous stem cell rescue for HD or NHL. Data were obtained from the bone marrow transplant (BMT) database at the City of Hope, and included the unique patient number (UPN), initial diagnosis, gender, date of birth, date of transplant, source of stem cells (bone marrow [BM], peripheral stem cells [PSC] or bone marrow and peripheral stem cells [BM+PSC]), and CD34+ cell dose. For patients who developed t-MDS/t-AML, the date of diagnosis and morphology were recorded. Slides of BM from all patients with t-MDS/t-AML were reviewed. FAB criteria were used for classification of MDS. Cytogenetic studies on BM or unstimulated blood samples were performed using standard methods followed by G-banding with trypsin-Giemsa. Karyotypes were interpreted using International System for Human Cytogenetic Nomenclature (ISCN), 1995.19 Karyotypes were considered normal diploid if no clonal abnormalities were detected in a minimum of 20 metaphases examined and if 2 independent cell-processing methods were used. Cumulative probabilities of developing t-MDS/t-AML over time were calculated using the Kaplan Meier technique.20 The log rank test was used to compare the various subpopulations. Cox regression techniques were used for calculating relative risk estimates. Variables included in the regression model were primary diagnosis, gender, age at transplant, source of stem cells, stem cell priming, and CD34+ cell dose. Age at transplant (< 40 versus  40 years) and CD34+ cell dose ( 3 × 106/kg versus > 3 × 106/kg) were taken as categorical variables. Because stem cell priming with VP-16 began in 1994 at City of Hope, the risk of developing t-MDS/t-AML was also assessed before and after 1994. This cohort provided us with a sampling frame from which to select controls for the case-control study. Case-control analysis For each of the t-MDS/t-AML cases, multiple controls (1-3) were randomly selected from within the cohort, using the following matching criteria: primary disease, age at transplant (± 2 years) and duration of follow-up (± 1 year). For the cases and controls so identified, the entire medical record (which occasionally consisted of records from more than 1 hospital if portions of treatment were provided elsewhere) was used to abstract clinical information important for assessing the characteristics and treatment of the malignancy before the transplant. The following data were collected: (1) disease characteristicsdiagnosis (histology), stage, and primary site; (2) treatment prior to transplant chemotherapydates, protocols/regimens, agents, dose schedules, routes of administration, and cumulative dose for selected agents (anthracyclines, alkylating agents, epipodophyllotoxins, etc); radiation therapydates, total dose, field, fractions, dose per fraction, equipment, and a copy of the institutional radiation therapy summary report; surgical and other proceduresa summary of all surgical procedures was completed and attached to a copy of institutional surgical reports; (3) priming regimens for stem cell mobilization; (4) source of stem cells; and (5) conditioning regimens usedradiation, chemotherapy. Analyses of the case-control study measured the degree of association of antecedent factors (eg, chemotherapy, radiation) with adverse outcome (t-MDS/t-AML) by estimation of odds ratios. Exact confidence limits of the odds ratios were calculated. Test for trend was used when analyzing categorical data ordered by degree of intensity or duration or both. Logistic regression was used to investigate the simultaneous effects of several variables. The variables included in the model were pretransplant exposures to alkylating agents and topoisomerase II inhibitors (quantification described below), source of stem cells, various conditioning regimens, and priming for stem cell collection with high-dose VP-16. We also conducted the case-control analysis after excluding patients who had received VP-16 priming, to explore further the association between pretransplant therapy and t-MDS/t-AML in the non-VP-16 primed group. Chemotherapy quantification An attempt was made to quantify an individual's exposure to all alkylating agents and topoisomerase II inhibitors. The following drugs were included in the alkylating agent category: nitrogen mustard, cyclophosphamide, chlorambucil, procarbazine, nitrosureas, triethylenemelamine, thiotepa, and dacarbazine. An alkylating agent dose score (AA score) was calculated for each patient (described by Meadows et al21). A single alkylating agent administered for 6 months was assigned a score of 100; for double alkylating agent therapy given for 6 months, a score of 200 was assigned, etc. Similarly, for assessing the topoisomerase exposure, the following drugs were included: etoposide and anthracyclines. A topoisomerase inhibitor dose score was calculated for each patient as follows: a single topoisomerase inhibitor used for 6 months was assigned a score of 100; for double topoisomerase inhibitor therapy given for 6 months, a score of 200 was assigned, etc. The alkylating agent and topoisomerase inhibitor scores were computed for each patient by summing all such scores corresponding to the patient's treatment course and rounding off to the nearest integer. The score thus was a measure of the amount of alkylating agent and topoisomerase inhibitor received as part of pretransplant therapy. VP-16 used as part of priming or conditioning regimens was not included in the above computed scores, but was analyzed separately.     Results Top Abstract Introduction Results Discussion References Cohort study As of July 1998, 60% of the cohort of 612 patients who had received HDT with stem cell rescue at the City of Hope were alive at time of last contact and had a median follow-up of 3.0 years (range, 0.1-10.6 years). The cohort had accrued 1406 person-years of follow-up from transplant. The median age at transplant for the entire cohort was 39.5 years (range, 6-69 years). Fifty-six percent of the cohort was male (Table 1).                                View this table: [in this window] [in a new window]   Table 1. Characteristics of the patient population (cohort study) Twenty-two patients developed morphologic evidence of t-MDS/t-AML at a median of 1.9 years from transplant and 3.8 years from diagnosis of the primary disease. Twenty of these patients had karyotypic abnormalities (abnormalities of chromosome 5 or 7 [n = 10], 11q23 or 21q22 abnormalities [n = 6] and other nonspecific abnormalities [n = 4]); 2 patients had normal cytogenetics. None of these 20 patients had karyotypic abnormalities before transplant. Of the 22 patients with morphologic evidence of t-MDS/t-AML, 6 had AML, 11 patients developed refractory anemia, 2 developed refractory anemia with excess blasts, 1 patient had refractory anemia with ringed sideroblasts, and 1 had refractory anemia with excess blasts in transformation. The remaining patient had trilineage dysplasia, associated with clonal karyotypic abnormalities including del (5), and unexplained persistent cytopenia. Eight patients underwent allogeneic or unrelated transplants after the development of t-MDS/t-AML. All patients received busulfan (4 mg/kg/d for 4 days) and cytoxan (60 mg/kg/d for 2 days). Total body irradiation was not used because all patients had received prior irradiation. Three patients died of regimen-related toxicity before day 100, 2 died of graft versus host disease (GVHD) at 2 and 5 months from transplant, and 1 patient died of relapsed MDS at 14 months from transplant. Two patients are alive and well at 18 and 24 months from BMT. Overall, of the 22 patients, 15 have died, with the median actuarial survival being 6 months from the diagnosis of t-MDS/t-AML (range, 1-24 months). The estimated cumulative probability for morphologic t-MDS/t-AML is shown in Figure 1, and was 8.6% ± 2.1% at 6 years. For the purpose of analysis, patients with morphologic t-MDS/t-AML were further categorized into those with cytogenetic abnormalities suggestive of alkylating agent-associated injury (5, del(5q) or 7, del(7q); n = 10) and those with abnormalities suggestive of topoisomerase II inhibitor-associated injury (11q23/21q22; n = 6). The cumulative probability of developing alkylating agent-associated t-MDS/t-AML approached 4.7% ± 1.7% at 6 years; that for topoisomerase II inhibitor-associated t-MDS/t-AML was 2.2% ± 0.9%. The median time to development of t-MDS/t-AML was 3.8 years from diagnosis and 2.6 years from transplant for alkylating agent-associated t-MDS/t-AML, and was 3.4 years from diagnosis and 0.9 years from transplant for topoisomerase II inhibitor associated t-AML. View larger version (8K): [in this window] [in a new window]   Fig 1. Cumulative probability of t-MDS/t-AML. The cumulative probability of the occurrence of morphologic t-MDS/t-AML is shown for 612 patients undergoing high-dose chemotherapy with autologous stem cell rescue for Hodgkin's disease and non-Hodgkin's lymphoma. Bars indicate standard errors. Risk factor analysis Univariate analysis revealed that age at transplant (< 40 years versus  40 years) was not associated with an increased risk of developing t-MDS/t-AML (RR = 1.1, P = 0.8). Patients who received PSC alone or BM + PSC following HDT were also not at an increased risk of developing t-MDS/t-AML as compared with patients who received autologous BM alone (RR = 1.2, P = 0.8). Among the recipients of PSC, those patients who received priming with VP-16 for stem cell mobilization (n = 61) were 4.7-fold more likely to develop t-MDS/t-AML as compared with patients who did not receive VP-16 priming (P = .005). Risk of developing t-AML with 11q23 abnormalities was also assessed for the "pre-priming era" (before 1994, n = 281) and the "priming era" (1994 and after, n = 331). There was a statistically significant increased risk of developing t-AML with 11q23 abnormalities among patients who underwent BMT during and after 1994, when priming with VP-16 was being used for stem cell collection (RR = 5.2, P = .03). Multivariate analysis revealed priming with VP-16 (RR = 7.7, 95% CI, 2.1-28.7, P = .002) to be independently associated with an increased risk of t-MDS/t-AML (Table 2). Source of stem cells (PSC versus BM), primary disease (HD versus NHL), age at transplant (< 40 years versus  40 years), and gender were not associated with an increased risk of t-MDS/t-AML.                                View this table: [in this window] [in a new window]   Table 2. Multivariate analysis of risk factors associated with t-MDS/t-AML (cohort study) PSC CD34+ cell dose and risk of t-MDS/t-AML Information on CD34+ cell dose was available for 258 of the 403 patients (64%) who had received PSC transplants. The median CD34+ cell dose was 3.6 × 106/kg (range, 0.14-57.3). There was a 3-fold increased risk of developing t-MDS/t-AML among patients who had a CD34+ cell dose that was less than or equal to 3 × 106 CD34+ cells/kg, as compared with those whose CD34+ cell dose exceeded 3 × 106/kg, but this did not reach statistical significance (P = 0.20). Priming with VP-16 for PSC collection Sixty-one patients (22 patients with HD and 39 patients with NHL) received priming with VP-16. These patients were further examined for therapy received before transplant to evaluate the role of prior therapy in this subgroup of patients. Fifty-two of the 61 (85%) patients received 2 g/m2 of VP-16 for priming; the other 9 received either 1 g/m2 or 1.5 g/m2. Priming with granulocyte colony-stimulating factor (G-CSF) alone before VP-16 was attempted in only 2 patients. Three patients developed t-AML in this cohort, and all 3 had 11q23 cytogenetic abnormalities. Pre-BMT chemotherapy was quantified as described under Materials and methods. No significant difference was found in the alkylating agent scores (a reflection of pretransplant alkylating agent exposure) between the patients who did (mean AA score 90) and did not develop t-AML (mean AA score 130, P = .30). Similarly, there was no difference in the topoisomerase score between those who did (mean topoisomerase score 77) and did not develop t-AML (mean topoisomerase score 57, P = .60). The conditioning regimens included Cytoxan, VP-16, and total body irradiation in 43 patients (70%) and Cytoxan, BCNU, and VP-16 in the other 18, and did not appear to influence the risk of t-AML (P = .50). Hodgkin's disease The median age at transplant for the 218 patients transplanted for HD was 32.2 years (range, 13-66 years) (see Table 1). Eleven patients developed t-MDS/t-AML with the estimated cumulative probability approaching 8.1% ± 2.5% at 6 years. The median time to development of t-MDS/t-AML was 3.8 years from diagnosis and 0.9 years from transplant. Multivariate analysis revealed priming with VP-16 to be the only independent factor associated with increased risk of t-MDS/t-AML (RR = 8.3, 95% CI 1.6 to 43.9, P = .01) (see Table 2). Non-Hodgkin's lymphoma The median age at transplant of the 394 patients with NHL was 44.6 years (range, 6-69 years; see Table 1). Eleven patients developed t-MDS/t-AML with the estimated cumulative probability approaching 9.1% ± 3.0% at 6 years. The median time to development of t-MDS/t-AML was 3.8 years from diagnosis and 2.4 years from transplant. Multivariate analysis failed to reveal any association between t-MDS/t-AML and the risk factors examined (see Table 2). Case-control study The characteristics of the cases and the controls are shown in Table 3; 64% of the cases and 40% of the controls had AA scores above the median (170) for the whole group. Fifty-five percent of the cases and 46% of the controls had topoisomerase II inhibitor scores above the median (110) for the entire group. The cases were more likely to have received radiation therapy before transplant (50%) as compared to the controls (29%). Again, for the purpose of analysis, patients with morphologic t-MDS/t-AML were further categorized into those with cytogenetic abnormalities suggestive of alkylating agent-associated injury (5, del(5q) or 7, del(7q)), and those with abnormalities suggestive of topoisomerase II inhibitor-associated injury (11q23/21q22 abnormality).                                View this table: [in this window] [in a new window]   Table 3. Characteristics of the patient population (case-control study) Risk factor analysis As seen in Table 4, multivariate analysis revealed an association between pretransplant radiation therapy and the risk of developing MDS/t-AML, especially among the cohort that had not received VP-16 priming (RR = 3.2, 95% CI, 1.0-10.2, P = .05). In addition, patients who had been primed with VP-16 for stem cell mobilization were at a 12.3-fold increased risk of developing t-AML with 11q23/21q22 abnormalities (P = .006).                                View this table: [in this window] [in a new window]   Table 4. Multivariate analysis of risk factors associated with t-MDS/t-AML (case-control study)     Discussion Top Abstract Introduction Results Discussion References High-dose chemoradiotherapy with stem cell rescue has emerged as the treatment of choice for patients with lymphoid malignancies who have suboptimal response to initial therapy or for patients with refractory or relapsed disease.1 With the increased success of this therapeutic option, there have been several reports of t-MDS/ t-AML.12-18 Some of the risk factors predicting an increased risk of t-MDS/t-AML following transplant have included older age at transplant,14,17 radiation therapy,15,16 and a low platelet count at transplant.16 It is unclear whether t-MDS/t-AML is related to pretransplant chemotherapy and radiotherapy, or transplant conditioning or stem cell priming regimens, or the source of stem cells, or is a cumulative effect of all of these exposures. This study evaluated whether pretransplant therapeutic exposures or transplant conditioning and stem cell priming regimens were associated with an increased risk of t-MDS/t-AML. Among the 612 patients who were treated with HDT and stem cell rescue at the City of Hope National Medical Center between 1986 and 1998 for HD and NHL, the cumulative risk of t-MDS/t-AML was 8.6% at 6 years for the entire cohort. The cumulative probability was 8.1% and 9.1% for patients with a primary diagnosis of HD and NHL, respectively. Therapy-related MDS/AML is a well-known late complication after conventional chemotherapy or radiation therapy for treatment of lymphoid malignancies.21-37 The incidence of t-MDS/t-AML following conventional chemotherapy ranges from 0.8% at 30 years37 to 6.3% at 20 years.26 Some of the factors associated with an increased risk of t-MDS/t-AML in this population include older age at diagnosis and treatment,24-26 alkylating agents,24,28 combined modality therapy (radiation and chemotherapy),29-32 epipodophyllotoxins,33,34 and splenectomy.26,35,36 The current nested case-control study offered more detailed information on exposure to various chemotherapeutic agents before transplant. To obtain an index of the total amount of the alkylating agents and topoisomerase II inhibitors received, we used a previously developed score as a method for combining different drugs. Summing the individual drug scores produced a measure of exposure. An attempt was made to evaluate the separate effects of individual alkylating agents and topoisomerase II inhibitors, but this was not possible because of small numbers and because drugs were frequently given in combination. No association was shown between pretransplant exposure to the various chemotherapeutic agents and t-MDS/ t-AML in this study. However, there was an association between radiation therapy given before transplant and the risk of developing t-MDS/t-AML, which was particularly apparent among patients who had not been primed with VP-16 for stem cell mobilization. Use of VP-16 has been shown to be an effective and safe method for mobilization of PSC and an effective agent in tumor reduction in patients with NHL and HD.41,42 VP-16 as a priming agent for PSC mobilization was initiated in 1994 at City of Hope, and so far 61 patients have received primed stem cell transplants. VP-16 was used for the dual purposes of cytoreduction and PSC mobilization. The dose of VP-16 used for priming in our study population was 2000 mg/m2 in 85% of this cohort and 1000 to 1500 mg/m2 in the rest. Patients were not randomized to priming with VP-16 and G-CSF versus G-CSF alone. Only 2 patients had failed initial priming attempts with G-CSF alone. Three patients who had received VP-16 priming developed t-AML, and all 3 had 11q23 cytogenetic abnormalities. This study demonstrated that priming with VP-16 was a predictor for t-AML with 11q23/21q22 abnormalities. There was a 5-fold increased risk of developing t-AML for patients transplanted after 1994, as compared with those transplanted before 1994, further suggesting a correlation between VP-16 priming and t-AML. Exposure to epipodophyllotoxins in a nontransplant setting has been associated with increased risk of AML, typically characterized by a short latency (median of 24-30 months), predominance of monocytic phenotypes (M4 and M5), and acute onset, often with a high blast count, rather than an initial myelodysplastic presentation.33-34,38-40 In addition, there appears to be a dose-intensity effect, with the risk of leukemia remaining low in patients receiving 2000 mg/m2 VP-16 or less, but increasing rapidly in patients receiving high doses, with greatly elevated risks among patients receiving more than 4000 mg/m2.38,43,44 Because VP-16 priming was not offered as part of a randomized study, we wanted to explore any differences in prior therapy that could have influenced the risk of developing t-AML. Therefore, patients who had received priming with VP-16 were examined for therapy received before transplant. There was no difference in the topoisomerase score between those that did and did not develop t-AML. In addition, there was no significant difference in the alkylating agent scores between the patients who did and did not develop t-AML. The conditioning regimens did not influence the risk of t-AML. However, the small number of events and the brief follow-up period for the cohort that received VP-16 priming allow us to ascribe only a limited significance to this risk factor. No association was seen between the conditioning regimens used and the risk of t-MDS/t-AML. Total body irradiation as a risk factor for t-MDS/t-AML has been reported previously.15,45 In our study, however, exposure to radiation as total body irradiation given as part of the myelosuppressive regimen for the transplant process was not a significant risk factor. Again, the failure to demonstrate an association could possibly be because of small numbers or because of a lack of heterogeneity in the treatment exposures received by the case and control populations. No pretransplant karyotypic abnormalities were detected among the patients who developed t-MDS/t-AML post-BMT. The onset of karyotypic abnormalities was after transplant in all patients who developed t-MDS/t-AML. Because the BM or PSC were not exposed to the transplant conditioning therapy, the source of the eventual cytogenetic abnormalities would therefore be either the transplanted autologous stem cells (injured by pretransplant chemotherapy or stem cell priming regimens or both) or residual marrow cells, assuming less than complete eradication of all endogenous bone marrow by the myeloablative conditioning regimens. At present no method is available to predict who is at increased risk for developing this complication, although there are reports in the literature attempting to identify populations at increased risk.46-48 Legare et al showed that clonality analysis can be predictive of the development of t-MDS/t-AMT after autologous transplant, and could potentially offer important insights into the pathogenesis and associated risk factors of t-MDS/t-AML.46 Abruzzese et al conducted a retrospective study examining pretransplant marrow or peripheral stem cells from 11 patients who subsequently developed myelodysplasia after HDT.47 To determine if the abnormal clone was present prior to HDT, they used fluorescent in situ hybridization to detect the cytogenetic markers observed at the onset of MDS. In 8 of the 11 cases, the same cytogenetic abnormality observed at the time of MDS diagnosis was detected in the pre-HDT specimen, thus supporting the hypothesis that stem cell damage leading to posttransplant MDS may result from prior conventional-dose chemotherapy. To formally prove the source of the myelodysplastic clone, however, we would have to genetically mark the graft,49 and eventually assay the myelodysplastic clone. Therapy-related MDS/AML is associated with a very poor outcome, with an estimated 12-month survival of 10%.50 This study has shown that patients undergoing HDT with stem cell rescue are at an increased risk of t-MDS/t-AML, especially those receiving priming with VP-16 for PSC collection. The use of increasingly intensive chemotherapy with stem cell support means that t-MDS/t-AML is likely to remain an important clinical problem. Appropriate surveillance of treatment-specific cohorts is essential to characterize the incidence and the risk factors for the occurrence of t-MDS/t-AML. Moreover, identification of populations with increased genetic susceptibility to leukemia may allow prevention or early treatment of t-MDS/t-AML.     Footnotes Submitted July 16, 1999; accepted November 8, 1999. Supported in part by grants CA 30206 and CA 33572 from the National Cancer Institute. Reprints: Smita Bhatia, Division of Pediatric Oncology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010-3000; e-mail: sbhatia{at}smtplink.coh.org. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.     References Top Abstract Introduction Results Discussion References 1. Laport GF, Williams SF. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol. 1988;25:503. 2. Fleury J, Legros M, Colombat PH, et al. High-dose chemotherapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease. Leuk Lymphoma. 1996;20:259[Medline] [Order article via Infotrieve]. 3. Carella AM, Carier P, Congiu A, et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant. 1991;8:31. 4. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BLNI randomized trial. Lancet. 1993;341:1051[Medline] [Order article via Infotrieve]. 5. Gribben JG, Linch DC, Singer AK, McMillan AK, Jarrett M, Goldstone AH. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood. 1989;73:340[Abstract/Free Full Text]. 6. Jagannath S, Dicke K, Armitage JO, et al. High-dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med. 1986;104:163. 7. Nademanee A, Schmidt GM, O'Donnell MR, et al. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. Blood. 1992;80:1130[Abstract/Free Full Text]. 8. Freedman AS, Takvorian T, Anderson KC, et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol. 1990;8:784[Abstract]. 9. Chopra R, Mcmillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood. 1993;81:1137[Abstract/Free Full Text]. 10. Philip T, Armitage JO, Spitzer G, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987;316:1493[Abstract]. 11. Stone RM. Myelodysplastic syndrome after autologous transplantation for lymphoma: The price of progress? Blood. 1994;83:3437[Free Full Text]. 12. Marolleau JP, Brice P, Morel P, Gisselbrecht C. Secondary acute myeloid leukemia after autologous bone marrow transplantation for malignant lymphoma. J Clin Oncol. 1991;11:590[Free Full Text]. 13. Traweek ST, Slovak ML, Nademanee AP, Brynes RK, Niland JC, Forman SJ. Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood. 1994;84:957[Abstract/Free Full Text]. 14. Bhatia S, Ramsay NKC, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87:3633[Abstract/Free Full Text]. 15. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12:2527[Abstract/Free Full Text]. 16. Stone RM, Neuberg D, Saiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994;12:2535[Abstract/Free Full Text]. 17. Andre M, Henry-Amar M, Blaise D, et al. for the Societe Francaise de Greffe de Moelle. Treatment-related deaths and second cancer risk after autologous stem cell transplantation for Hodgkin's disease. Blood. 1998;92:1933[Abstract/Free Full Text]. 18. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood. 1994;83:3780[Abstract/Free Full Text]. 19. Mitelman F, ed. ICSN (1995): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger; 1995. 20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457. 21. Meadows AT, Obringer AC, Marrero O, et al. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors. Med Pediatr Oncol. 1989;17:477[Medline] [Order article via Infotrieve]. 22. Travis LB, Curtis RE, Glimelius B, et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst. 1993;85:1932[Abstract/Free Full Text]. 23. Boivin JF, Hutchison GB, Zauber AG. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst. 1995;87:732[Abstract/Free Full Text]. 24. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334:745[Abstract/Free Full Text]. 25. Pedreson-Bjergaard J, Larsen S. Incidence of acute nonlymphocytic, preleukemia, and acute myeloproliferative syndrome up to 10 years after the treatment of Hodgkin's disease. N Engl J Med. 1982;307:965[Abstract]. 26. van Leeuwen FE, Chorus AM, van den Belt-Dusebout AW, et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol. 1994;12:1063[Abstract/Free Full Text]. 27. Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol. 1986;4:830[Abstract/Free Full Text]. 28. Tucker MA, Meadows AT, Boice JD, et al. for the Late Effects Study Group. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst. 1987;78:459. 29. Cimino G, Papa G, Tura S, et al. Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. J Clin Oncol. 1991;9:432[Abstract]. 30. Andrieu JM, Ifrah N, Payen C, Fermanian J, Coscas Y, Flandrin G. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol. 1990;8:1148[Abstract]. 31. Lavey RS, Eby NL, Prosnitz LR. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer. 1990;66:80[Medline] [Order article via Infotrieve]. 32. Curtis RE, Boice JD, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992;326:1745[Abstract]. 33. Pui C-H, Ribiero RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682[Abstract]. 34. Winick NJ, McKenn RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol. 1993;11:209[Abstract/Free Full Text]. 35. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988;318:76[Abstract]. 36. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease. N Engl J Med. 1990;322:7[Abstract]. 37. Sankila R, Garwicz S, Olsen JH, et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol. 1996;14:1442[Abstract/Free Full Text]. 38. Pederson-Bjergaard J, Hansen S, Larsen S, Daugaard G, Philip P, Rorth M. Increased risk of myelodysplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumors. Lancet. 1991;338:359[Medline] [Order article via Infotrieve]. 39. Bajorin D, Motzer R, Rodriguez E, Murphy B, Bosl G. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst. 1993;85:60[Free Full Text]. 40. Pui C, Hancock ML, Raimondi SC, et al. Myeloid neoplasia in children treated for solid tumors. Lancet. 1990;336:417[Medline] [Order article via Infotrieve]. 41. Copelan EA, Ceselski SK, Ezzone SA, et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol. 1997;15:759[Abstract/Free Full Text]. 42. Kanfer EJ, McGuigan D, Samson D, et al. High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels. Br J Cancer. 1998;78:928[Medline] [Order article via Infotrieve]. 43. Nichols C, Breeden E, Loerher P, Williams S, Einhorn L. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst. 1993;85:36[Abstract/Free Full Text]. 44. Haupt R, Fears TR, Heise A, et al. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German population. Int J Cancer. 1997;71:9[Medline] [Order article via Infotrieve]. 45. Travis LB, Weeks J, Curtis RE, et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol. 1996;14:565[Abstract/Free Full Text]. 46. Legare RD, Gribben JG, Maragh M, et al. Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. Am J Hematol. 1997;56:45[Medline] [Order article via Infotrieve]. 47. Abruzzese E, Radford JE, Miller JS, et al. Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood. 1999;94:1814[Abstract/Free Full Text]. 48. Chao NJ, Nademanee AP, Long GD, et al. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. J Clin Oncol. 1991;9:1575[Abstract]. 49. Brenner MK, Rill DR, Holladay MS, et al. Gene marking to determine whether autologous marrow infusion restores long-term hemopoiesis in cancer patients. Lancet. 1993;342:1134[Medline] [Order article via Infotrieve]. 50. Neugut A, Robinson E, Nieves J, et al. Poor survival of treatment-related acute nonlymphocytic leukemia. JAMA. 1990;264:1006[Abstract/Free Full Text]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Gisselbrecht, J. Vose, A. Nademanee, A. M. Gianni, and A. Nagler Radioimmunotherapy for Stem Cell Transplantation in Non-Hodgkin's Lymphoma: In Pursuit of a Complete Response Oncologist, October 1, 2009; 14(suppl_2): 41 - 51. [Abstract] [Full Text] [PDF] J. N. Winter, D. J. Inwards, S. Spies, G. Wiseman, D. Patton, W. Erwin, A. W. Rademaker, B. B. Weitner, S. F. Williams, M. S. Tallman, et al. Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma J. Clin. Oncol., April 1, 2009; 27(10): 1653 - 1659. [Abstract] [Full Text] [PDF] S. Chakraborty, C.-L. Sun, L. Francisco, M. Sabado, L. Li, K. L. Chang, S. Forman, S. Bhatia, and R. Bhatia Accelerated Telomere Shortening Precedes Development of Therapy-Related Myelodysplasia or Acute Myelogenous Leukemia After Autologous Transplantation for Lymphoma J. Clin. Oncol., February 10, 2009; 27(5): 791 - 798. [Abstract] [Full Text] [PDF] B. Barlogie, G. Tricot, J. Haessler, F. van Rhee, M. Cottler-Fox, E. Anaissie, J. Waldron, M. Pineda-Roman, R. Thertulien, M. Zangari, et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989 Blood, January 1, 2008; 111(1): 94 - 100. [Abstract] [Full Text] [PDF] S. Bhatia, L. Francisco, A. Carter, C.-L. Sun, K. S. Baker, J. G. Gurney, P. B. McGlave, A. Nademanee, M. O'Donnell, N. K. C. Ramsay, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study Blood, November 15, 2007; 110(10): 3784 - 3792. [Abstract] [Full Text] [PDF] A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma J. Clin. Oncol., April 10, 2007; 25(11): 1396 - 1402. [Abstract] [Full Text] [PDF] C. Sebban, N. Mounier, N. Brousse, C. Belanger, P. Brice, C. Haioun, H. Tilly, P. Feugier, R. Bouabdallah, C. Doyen, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Blood, October 15, 2006; 108(8): 2540 - 2544. [Abstract] [Full Text] [PDF] M. Kalaycio, L. Rybicki, B. Pohlman, R. Sobecks, S. Andresen, E. Kuczkowski, and B. Bolwell Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia J. Clin. Oncol., August 1, 2006; 24(22): 3604 - 3610. [Abstract] [Full Text] [PDF] E. A. Copelan Hematopoietic stem-cell transplantation. N. Engl. J. Med., April 27, 2006; 354(17): 1813 - 1826. [Full Text] [PDF] D. L. Forrest, D. E. Hogge, T. J. Nevill, S. H. Nantel, M. J. Barnett, J. D. Shepherd, H. J. Sutherland, C. L. Toze, C. A. Smith, J. C. Lavoie, et al. High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation J. Clin. Oncol., November 1, 2005; 23(31): 7994 - 8002. [Abstract] [Full Text] [PDF] R. Bhatia, K. Van Heijzen, A. Palmer, A. Komiya, M. L. Slovak, K. L. Chang, H. Fung, A. Krishnan, A. Molina, A. Nademanee, et al. Longitudinal Assessment of Hematopoietic Abnormalities After Autologous Hematopoietic Cell Transplantation for Lymphoma J. Clin. Oncol., September 20, 2005; 23(27): 6699 - 6711. [Abstract] [Full Text] [PDF] S. Bhatia, L. L. Robison, L. Francisco, A. Carter, Y. Liu, M. Grant, K. S. Baker, H. Fung, J. G. Gurney, P. B. McGlave, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study Blood, June 1, 2005; 105(11): 4215 - 4222. [Abstract] [Full Text] [PDF] J. R. Brown, H. Yeckes, J. W. Friedberg, D. Neuberg, H. Kim, L. M. Nadler, and A. S. Freedman Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma J. Clin. Oncol., April 1, 2005; 23(10): 2208 - 2214. [Abstract] [Full Text] [PDF] A. T. Look Molecular Pathogenesis of MDS Hematology, January 1, 2005; 2005(1): 156 - 160. [Abstract] [Full Text] [PDF] G. Lenz, M. Dreyling, E. Schiegnitz, T. Haferlach, J. Hasford, M. Unterhalt, and W. Hiddemann Moderate Increase of Secondary Hematologic Malignancies After Myeloablative Radiochemotherapy and Autologous Stem-Cell Transplantation in Patients With Indolent Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group J. Clin. Oncol., December 15, 2004; 22(24): 4926 - 4933. [Abstract] [Full Text] [PDF] J. Czyz, R. Dziadziuszko, W. Knopinska-Postuszuy, A. Hellmann, L. Kachel, J. Holowiecki, J. Gozdzik, J. Hansz, A. Avigdor, A. Nagler, et al. Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients Ann. Onc., August 1, 2004; 15(8): 1222 - 1230. [Abstract] [Full Text] [PDF] S. M. Smith, M. M. Le Beau, D. Huo, T. Karrison, R. M. Sobecks, J. Anastasi, J. W. Vardiman, J. D. Rowley, and R. A. Larson Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series Blood, July 1, 2003; 102(1): 43 - 52. [Abstract] [Full Text] [PDF] J. O. Armitage, P. P. Carbone, J. M. Connors, A. Levine, J. M. Bennett, and S. Kroll Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin's Lymphoma Patients J. Clin. Oncol., March 1, 2003; 21(5): 897 - 906. [Abstract] [Full Text] [PDF] C. Metayer, R. E. Curtis, J. Vose, K. A. Sobocinski, M. M. Horowitz, S. Bhatia, J. W. Fay, C. O. Freytes, S. C. Goldstein, R. H. Herzig, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study Blood, March 1, 2003; 101(5): 2015 - 2023. [Abstract] [Full Text] [PDF] V. Diehl Advanced Hodgkin's Disease: ABVD Is Better, Yet Is Not Good Enough! J. Clin. Oncol., February 15, 2003; 21(4): 583 - 585. [Full Text] [PDF] M. Hunault-Berger, N. Ifrah, and P. Solal-Celigny Intensive therapies in follicular non-Hodgkin lymphomas Blood, July 30, 2002; 100(4): 1141 - 1152. [Full Text] [PDF] S. Montoto, A. Lopez-Guillermo, A. Ferrer, M. Camos, A. Alvarez-Larran, F. Bosch, J. Blade, F. Cervantes, J. Esteve, F. Cobo, et al. Survival after progression in patients with follicular lymphoma: analysis of prognostic factors Ann. Onc., April 1, 2002; 13(4): 523 - 530. [Abstract] [Full Text] [PDF] C. Hosing, M. Munsell, S. Yazji, B. Andersson, D. Couriel, M. de Lima, M. Donato, J. Gajewski, S. Giralt, M. Korbling, et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma Ann. Onc., March 1, 2002; 13(3): 450 - 459. [Abstract] [Full Text] [PDF] H. C. Fung, A. P. Nademanee, S. Bhatia, S. J. Forman, A. Sureda, and E. Conde Is There an Association Between Total-Body Irradiation and Secondary Acute Myelogenous Leukemia/Myelodysplastic Syndrome in Patients With Relapsed/Refractory Hodgkin's Disease Treated With Autologous Stem-Cell Transplantation? J. Clin. Oncol., August 1, 2001; 19(15): 3585 - 3588. [Full Text] D. M. Lillington, I. N.M. Micallef, E. Carpenter, M. J. Neat, J. A.L. Amess, J. Matthews, N. J. Foot, B. D. Young, T. A. Lister, and A. Z.S. Rohatiner Detection of Chromosome Abnormalities Pre-High-Dose Treatment in Patients Developing Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After Treatment for Non-Hodgkin's Lymphoma J. Clin. Oncol., May 1, 2001; 19(9): 2472 - 2481. [Abstract] [Full Text] [PDF] O. W. Press, J. F. Eary, T. Gooley, A. K. Gopal, S. Liu, J. G. Rajendran, D. G. Maloney, S. Petersdorf, S. A. Bush, L. D. Durack, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Blood, November 1, 2000; 96(9): 2934 - 2942. [Abstract] [Full Text] [PDF] H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585. [Full Text] [PDF] N. Mounier, C. Gisselbrecht, J. W. Friedberg, D. Neuberg, and A. S. Freedman Myelodysplasia After Autotransplantation J. Clin. Oncol., October 19, 2000; 18(19): 3446 - 3447. [Full Text] [PDF] J. Pedersen-Bjergaard, M. K. Andersen, and D. H. Christiansen Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation Blood, June 1, 2000; 95(11): 3273 - 3279. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Krishnan, A. Articles by Forman, S. J. Search for Related Content PubMed PubMed Citation Articles by Krishnan, A. Articles by Forman, S. J. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020